OCUL-101

N/A

Report date: 2026/04/17 20:02:02

Base Information

Drug NameOCUL-101
Drug Alias NameOCUL101
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionComplement C5 inhibitorsVascular endothelial growth factor receptor antagonists
TargetsComplement C5Vascular endothelial growth factor receptor
Therapy Area/IndicationsDiabetic macular oedemaRetinal NeovascularizationGeographic Atrophy +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShenzhen Oukejian Biomedical Technology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShenzhen Oukejian Biomedical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetic macular oedemaRetinal NeovascularizationGeographic Atrophy +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A